Immune

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue, where it is produced as a fragment of a larger precursor protein called prothymosin alpha. A synthetic version, thymalfasin, is a licensed prescription medicine in a number of countries, though not in the United States. That puts it in an unusual position for this field: better credentialled than most research peptides, and still not FDA-approved.

How it works is described in the published literature mainly in terms of T-cell maturation and toll-like receptor signalling, and that description is considerably more complete in cell and animal work than in humans. Mechanism and effect are separate claims. This is a compound where the mechanistic account has run well ahead of the clinical one in the English-language record, which is a pattern worth recognising rather than a reason to dismiss the work.

One distinction is worth drawing before anything else: thymosin alpha-1 and thymosin beta-4 share a name and almost nothing else. They come from different precursor proteins, have different sequences and different lengths, and are studied for different reasons. Treating them as two versions of one compound is a common error, and it makes every claim downstream of it unreliable. We have not yet published a class review for immune peptides, so the reading below covers the foundations and the nearest adjacent class.